1. PRODUCT NAME

ELONVA® 100 micrograms solution for injection

ELONVA® 150 micrograms solution for injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each pre-filled syringe contains 100 micrograms or 150 micrograms of corifollitropin alfa in 0.5 mL solution for injection.

Corifollitropin alfa, a gonadotrophin designed as a sustained follicle stimulant is a glycoprotein consisting of two non-covalently linked non-identical subunits called α and β. The α-subunit is identical to that of human follicle-stimulating hormone (FSH); the β-subunit is composed of the complete β-subunit of human FSH (residues 1-111) extended with the carboxy-terminal peptide (CTP) of the β–subunit of human chorionic gonadotropin (hCG) (residues 118-145). CAS No.: 195962-23-3.

α-subunit

APDVQDCPEC TLQENPFFSQ PGAPILQCMG CCFSRAYPTP

*                         *
LRSKKTMLVQ KNVTSESTCC VAKSYRVT VMGGFKVENHT

ACHCSTCYYH KS

β-subunit

*                  *
NSCELTNITI AIEKEECRFC ISINTTWAG YCYTRDLVYK

DPARPKIQT CTFKEKLYET VRVPGCAHHA DSLYTPVAT

& &
QCHCGKCDSD STDCTVRLG PSYCSFEMK ESSSKAFFP

&     &    &
SLPSPSRLPG PSDTPILPQ

* = N-glycosylation sites
& = O-glycosylation sites

Corifollitropin alfa is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology, using a chemically defined cell culture medium without the addition of antibiotics, human- or animal-derived proteins (protein-free) or any other components of human or animal origin.

Excipient(s) with known effect:
ELONVA contains less than 1 mmol sodium (23 mg) per injection, i.e. essentially ‘sodium-free’.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Solution for injection.

Clear and colourless aqueous solution.
4. CLINICAL PARTICULARS

4.1 Therapeutic indications
Controlled Ovarian Stimulation (COS) for the development of multiple follicles and pregnancy in women undergoing in vitro fertilisation techniques.

4.2 Dose and method of administration
Treatment with ELONVA should be initiated under the supervision of a physician experienced in the treatment of fertility problems.

ELONVA may be administered by the woman herself or her partner, provided that proper instructions are given by the physician. Self-administration of ELONVA should only be performed by women who are well-motivated, adequately trained and with access to expert advice.

Do not use if the solution contains particles or if the solution is not clear.

In the treatment of women of reproductive age, the dose of ELONVA is based on weight and age.

A single 100-microgram dose is recommended in women who weigh less than or equal to 60 kilograms and who are 36 years of age or younger.

A single 150-microgram dose is recommended in women:
- who weigh more than 60 kilograms, regardless of age.
- who weigh 50 kilograms or more and who are older than 36 years of age.

Women older than 36 years of age who weighed less than 50 kilograms were not studied.

<table>
<thead>
<tr>
<th>Body Weight</th>
<th>Less than 50 kg</th>
<th>50 – 60 kg</th>
<th>More than 60 kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>36 years or younger</td>
<td>100 micrograms</td>
<td>100 micrograms</td>
<td>150 micrograms</td>
</tr>
<tr>
<td>Older than 36 years</td>
<td>Not studied.</td>
<td>150 micrograms</td>
<td>150 micrograms</td>
</tr>
</tbody>
</table>

The recommended doses of ELONVA have only been established in a treatment cycle with a GnRH antagonist that was administered from stimulation day 5 or day 6 onwards (see also sections 4.4 and 5.1).

*Stimulation day 1:*
ELONVA should be administered as a single subcutaneous injection, preferably in the abdominal wall, during the early follicular phase of the menstrual cycle.

*Stimulation day 5 or 6:*
Treatment with Gonadotrophin Releasing Hormone (GnRH) antagonist should be started on stimulation day 5 or day 6 depending on the ovarian response, i.e. the number and size of growing follicles. The concurrent determination of serum oestradiol levels may also be useful. The GnRH antagonist is used to prevent premature Luteinising Hormone (LH) surges.

*Stimulation day 8:*
Seven days after the injection with ELONVA on stimulation day 1, COS treatment may be continued with daily injections of (rec)FSH until the criterion for triggering final oocyte maturation (3 follicles ≥ 17 mm) has been reached. The daily dose of (rec)FSH may depend on the ovarian response, which should be monitored by regular ultrasonographic assessments from stimulation day 5 or 6 onwards. In normal responders a daily dose of 150 IU (rec)FSH is advised. Administration of (rec) FSH on the day of human Chorionic Gonadotrophin (hCG) administration can be omitted, depending on the
ovarian response. In general, adequate follicular development is achieved on average by the ninth day of treatment (range 6 to 18 days).

As soon as three follicles > 17 mm are observed, a single injection of 5,000 up to 10,000 IU urinary hCG is administered the same day or the day thereafter to induce final oocyte maturation. In case of an excessive ovarian response, see the recommendation given in section 4.4 in order to reduce the risk for developing ovarian hyperstimulation syndrome (OHSS).

Special populations
Renal impairment: No clinical studies have been performed in patients with renal insufficiency. Since the rate of elimination of corifollitropin alfa maybe reduced in patients with renal insufficiency, the use of ELONVA in these women is not recommended (see section 4.4 and section 5.2).

Hepatic impairment: Although data in hepatically impaired patients are not available, hepatic impairment is unlikely to affect the elimination of corifollitropin alfa (see section 5.2).

4.3 Contraindications
• Tumours of the ovary, breast, uterus, pituitary or hypothalamus.
• Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause.
• Primary ovarian failure.
• Ovarian cysts or enlarged ovaries.
• A history of Ovarian Hyperstimulation Syndrome (OHSS)
• A previous COS cycle that resulted in more than 30 follicles > 11 mm measured by ultrasound examination.
• A basal antral follicle count > 20.
• Fibroid tumours of the uterus incompatible with pregnancy.
• Malformations of the reproductive organs incompatible with pregnancy.
• Pregnancy or lactation (see section 4.4).
• Polycystic ovarian syndrome (PCOS).
• Hypersensitivity to the active substance or to any of the excipients.

4.4 Special warnings and precautions for use

Infertility Evaluation Before Starting Treatment
Before starting treatment, the couple's infertility should be assessed as appropriate. In particular, women should be evaluated for hypothyroidism, adrenocortical insufficiency, hyperprolactinemia and pituitary or hypothalamic tumours, and appropriate specific treatment given. Medical conditions that contraindicate pregnancy should also be evaluated before starting treatment with ELONVA.

Dosing During the Stimulation Cycle
ELONVA is intended for single subcutaneous injection only. Additional injections of ELONVA should not be given within the same treatment cycle (see section 4.2).

After administration of ELONVA, no additional FSH-containing products should be administered prior to stimulation day 8 (see section 4.2).

Renal Insufficiency
In patients with renal insufficiency the rate of elimination of corifollitropin alfa may be reduced. Therefore, the use of ELONVA in these women is not recommended (see section 4.2 and section 5.2).

Not Recommended with a GnRH Agonist Protocol
There are limited data on the use of ELONVA in combination with a Gonadotrophin Releasing Hormone (GnRH) agonist. Therefore, the use of ELONVA is not recommended in combination with a GnRH agonist (see section 4.2).
Ovarian Hyperstimulation Syndrome (OHSS)

OHSS is a medical event distinct from uncomplicated ovarian enlargement. Clinical signs and symptoms of mild and moderate OHSS are abdominal pain, nausea, diarrhoea, mild to moderate enlargement of ovaries and ovarian cysts. Severe OHSS may be life-threatening. Clinical signs and symptoms of severe OHSS are large ovarian cysts, acute abdominal pain, ascites, pleural effusion, hydrothorax, dyspnoea, oliguria, haematological abnormalities and weight gain. In rare instances, venous or arterial thromboembolism may occur in association with OHSS. Transient liver function test abnormalities suggestive of hepatic dysfunction with or without morphologic changes on liver biopsy have also been reported in association with OHSS.

OHSS may be caused by administration of human Chorionic Gonadotrophin (hCG) and by pregnancy (endogenous hCG). Early OHSS usually occurs within 10 days after hCG administration and may be associated with an excessive ovarian response to gonadotrophin stimulation. Late OHSS occurs more than 10 days after hCG administration, as a consequence of the hormonal changes with pregnancy. Because of the risk of developing OHSS, patients should be monitored for at least two weeks after hCG administration.

Women with known risk factors for a high ovarian response may be especially prone to the development of OHSS during or following treatment with ELONVA. For women having their first cycle of ovarian stimulation, for whom risk factors are only partially known, close observation for early signs and symptoms of OHSS is recommended.

To reduce the risk of OHSS, ultrasonographic assessments of follicular development should be performed prior to treatment and at regular intervals during treatment. The concurrent determination of serum oestradiol levels may also be useful. In ART there is an increased risk of OHSS with 18 or more follicles of 11 mm or more in diameter. When there are 30 or more follicles in total it is advised to withhold hCG administration.

Depending on the ovarian response, the following measures can be considered to reduce the risk of OHSS:
- withhold further stimulation with a gonadotrophin for a maximum of 3 days (coasting);
- withhold hCG and cancel the treatment cycle;
- administer a dose lower than 10,000 IU of urinary hCG for triggering final oocyte maturation, e.g. 5,000 IU urinary hCG or 250 micrograms rec-hCG (which is equivalent to approximately 6,500 IU of urinary hCG);
- cancel the fresh embryo transfer and cryopreserve embryos;
- avoid administration of hCG for luteal phase support.

Adherence to the recommended ELONVA dosage and treatment regimen and careful monitoring of ovarian response is important to reduce the risk of OHSS. If OHSS develops, standard and appropriate management of OHSS should be implemented and followed.

Ovarian Torsion

Ovarian torsion has been reported after treatment with gonadotrophins, including ELONVA. Ovarian torsion may be related to other conditions, such as OHSS, pregnancy, previous abdominal surgery, past history of ovarian torsion, and previous or current ovarian cysts. Damage to the ovary due to reduced blood supply can be limited by early diagnosis and immediate detorsion.

Multi-foetal Gestation and Birth

Multiple pregnancies and births have been reported for all gonadotrophin treatments, including ELONVA. The woman and her partner should be advised of the potential risks for the mother (pregnancy and delivery complications) and the neonate (low birth weight) before starting treatment. In women undergoing ART procedures the risk of multiple pregnancy is mainly related to the number of embryos transferred.

Ectopic Pregnancy

Infertile women undergoing ART have an increased incidence of ectopic pregnancies. It is important to have early ultrasound confirmation that a pregnancy is intrauterine, and to exclude the possibility of extrauterine pregnancy.
Congenital Malformations
The incidence of congenital malformations after ART may be slightly higher than after spontaneous conceptions. This is thought to be due to differences in parental characteristics (e.g. maternal age, sperm characteristics) and the higher incidence of multiple pregnancies.

Ovarian and Other Reproductive System Neoplasms
There have been reports of ovarian and other reproductive system neoplasms, both benign and malignant, in women who have undergone multiple treatment regimens for infertility treatment. It is not established whether or not treatment with gonadotrophins increases the risk of these tumours in infertile women.

Vascular Complications
Thromboembolic events, both in association with and separate from OHSS, have been reported following treatment with gonadotrophins, including ELONVA. Intravascular thrombosis, which may originate in venous or arterial vessels, can result in reduced blood flow to vital organs or the extremities. In women with generally recognized risk factors for thromboembolic events, such as a personal or family history, severe obesity or thrombophilia, treatment with gonadotrophins including ELONVA may further increase this risk. In these women the benefits of gonadotrophin administration, including ELONVA, need to be weighed against the risks. It should be noted, however, that pregnancy itself also carries an increased risk of thrombosis.

4.5 Interaction with other medicines and other forms of interaction

Interactions with other medicines
No interaction studies with ELONVA and other medicines have been performed. Since corifollitropin alfa is not a substrate of cytochrome P450 enzymes, no metabolic interactions with other medicinal products are anticipated.

ELONVA may cause a false positive hCG pregnancy test if the test is administered during the ovarian stimulation portion of the ART cycle. This may be due to cross-reactivity of some hCG pregnancy tests with the carboxy-terminal peptide of the beta subunit of ELONVA.

4.6 Fertility, pregnancy and lactation

Use in pregnancy (Category B3)
The use of ELONVA during pregnancy is contraindicated. In case of inadvertent exposure during pregnancy, clinical data are not sufficient to exclude a teratogenic effect of corifollitropin alfa.

Use in lactation
The use of ELONVA during lactation is contraindicated.

Effects on fertility
Corifollitropin alfa administered to rats and rabbits prior to mating did not impair fertility; treatment stimulated the development of multiple follicles.

4.7 Effects on ability to drive and use machines

Effect on ability to drive and use machines
No studies on the ability to drive and use machines have been performed.

ELONVA may cause dizziness. Patients should be advised that if they feel dizzy, they should not drive or use machines.

4.8 Undesirable effects
The most frequently reported adverse drug reactions during treatment with ELONVA in clinical trials (N=2,397) are pelvic discomfort (6.0%), OHSS (4.3% see section 4.2), headache (4.0%), nausea (2.3%), fatigue (1.5%), and breast tenderness (1.3%).
The table below displays the main adverse drug reactions in women treated with ELONVA in clinical trials according to body system and frequency: common (≥1%, <10%), uncommon (≥0.1%, <1%).

<table>
<thead>
<tr>
<th>Body system</th>
<th>Frequency</th>
<th>Undesirable effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychiatric disorders</td>
<td>Uncommon</td>
<td>Mood swings</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Common</td>
<td>Headache</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Dizziness</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Uncommon</td>
<td>Hot flush</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Common</td>
<td>Nausea</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Abdominal distension, vomiting, diarrhoea, constipation.</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>Uncommon</td>
<td>Back pain</td>
</tr>
<tr>
<td>Pregnancy, puerperium and perinatal conditions</td>
<td>Uncommon</td>
<td>Abortion spontaneous</td>
</tr>
<tr>
<td>Reproductive system and breast disorders</td>
<td>Common</td>
<td>OHSS, pelvic pain, pelvic discomfort, breast tenderness</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Ovarian torsion, adnexa uteri pain, premature ovulation, breast pain</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Common</td>
<td>Fatigue</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Injection site haematoma, injection site pain, irritability</td>
</tr>
<tr>
<td>Investigations</td>
<td>Uncommon</td>
<td>Alanine aminotransferase increased, aspartate aminotransferase increased</td>
</tr>
<tr>
<td>Injury, poisoning and procedural complications</td>
<td>Uncommon</td>
<td>Procedural pain</td>
</tr>
</tbody>
</table>

There have been post-marketing reports of hypersensitivity reactions, both local and generalised, including rash.

In addition, ectopic pregnancy and multiple gestations have been reported. These are considered to be related to ART or subsequent pregnancy.

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions [https://nzphvc.otago.ac.nz/reporting/](https://nzphvc.otago.ac.nz/reporting/).

**4.9 Overdose**

More than one injection of ELONVA within one treatment cycle or too high a dose of ELONVA and/or (rec)FSH may increase the risk of OHSS (see section 4.4). After administration of ELONVA, no additional FSH-containing product should be administered prior to stimulation day 8, as this may also increase the risk of OHSS. For measures to reduce the risk of and manage OHSS see section 4.4.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).
5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic Group: gonadotrophins
ATC code: G03GA09 corifollitropin alfa.

Mechanism of action

Corifollitropin alfa has the same pharmacodynamic profile as (rec)FSH, but with a markedly prolonged duration of FSH activity due to a relatively long elimination half-life. This was achieved by the addition of the carboxy-terminal peptide (CTP) of the beta-subunit of hCG to the beta-chain of human FSH. Due to its ability to initiate and sustain multiple follicular growth for an entire week, a single subcutaneous injection of the recommended dose of ELONVA may replace the first seven injections of any daily (rec)FSH preparation in a COS treatment cycle. Corifollitropin alfa does not display any intrinsic luteinising hormone (LH)/hCG activity.

Clinical efficacy and safety

In three randomised, double-blind, clinical trials (ENSURE, ENGAGE, and PURSUE), treatment with a single subcutaneous injection of ELONVA, 100 micrograms (ENSURE study) or 150 micrograms (ENGAGE and PURSUE study), for the first seven days of COS was compared to treatment with a daily dose of 150, 200, or 300 IU of recFSH, respectively. Pituitary suppression with a GnRH antagonist (ganirelix acetate injection at a daily dose of 0.25 mg) was used in each of the three clinical trials.

In the ENSURE study, 396 healthy normal ovulatory women, aged 18 to 36 years with a body weight less than or equal to 60 kg, were treated for one cycle with 100 micrograms of ELONVA and pituitary suppression with a GnRH antagonist as part of an ART program. The primary efficacy endpoint was number of oocytes retrieved. The median total duration of stimulation was 9 days for both groups, indicating that two days of recFSH were required to complete ovarian stimulation from stimulation day 8 onwards (recFSH was given on the day of hCG for this study).

In the ENGAGE study, 1,506 healthy normal ovulatory women, aged 18 to 36 years with a body weight greater than 60 kg and less than or equal to 90 kg, were treated for one cycle with 150 micrograms of ELONVA and pituitary suppression with a GnRH antagonist as part of an ART program. The co-primary efficacy endpoints were ongoing pregnancy rate and number of oocytes retrieved. The median total duration of stimulation was 9 days for both groups, indicating that two days of recFSH were required to complete ovarian stimulation from stimulation day 8 onwards (recFSH was given on the day of hCG for this study).

In the PURSUE study, 1,390 healthy normal ovulatory women, aged 35 to 42 years with a body weight greater than or equal to 50 kg, were treated for one cycle with 150 micrograms of ELONVA and pituitary suppression with a GnRH antagonist as part of an ART program. The primary efficacy endpoint was vital pregnancy rate. The number of oocytes retrieved was a key secondary efficacy endpoint. The median total duration of stimulation was 9 days for both groups, indicating that one day of recFSH was required to complete ovarian stimulation from stimulation day 8 onwards (no recFSH was given on the day of hCG for this study).

Number of oocytes retrieved

In all three studies, treatment with a single injection of ELONVA, 100 or 150 micrograms, for the first seven days of COS, resulted in a higher number of oocytes retrieved compared with a daily dose of recFSH. However, the differences were within the predefined equivalence (ENGAGE and ENSURE) or non-inferiority (PURSUE) margins. See Table 1 below.
Table 1: Mean Number of Oocytes Retrieved from ENSURE, ENGAGE, and PURSUE Intent-to-Treat Population (ITT)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>ENSURE (18-36 years of age) (body weight less than or equal to 60 kg)</th>
<th>ENGAGE (18-36 years of age) (body weight greater than 60 kg and less than or equal to 90 kg)</th>
<th>PURSUE (35-42 years of age) (body weight greater than or equal to 50 kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ELONVA 100 µg recFSH 150 IU</td>
<td>ELONVA 150 µg recFSH 200 IU</td>
<td>ELONVA 150 µg recFSH 300 IU</td>
</tr>
<tr>
<td>N=268</td>
<td>N=128</td>
<td>N=756</td>
<td>N=694</td>
</tr>
<tr>
<td>Mean number of oocytes</td>
<td>13.3</td>
<td>13.8</td>
<td>10.7</td>
</tr>
<tr>
<td>Difference [95% CI]</td>
<td>2.5 [1.2; 3.9]</td>
<td>1.2 [0.5, 1.9]</td>
<td>0.5 [-0.2, 1.2]</td>
</tr>
</tbody>
</table>

Pregnancy from the fresh cycles of ENGAGE and PURSUE

In the ENGAGE study, non-inferiority was demonstrated in ongoing pregnancy rates between ELONVA and recFSH, with ongoing pregnancy rate defined as presence of at least one foetus with heart activity assessed at least 10 weeks after embryo transfer.

In the PURSUE study, non-inferiority was demonstrated in vital pregnancy rate between ELONVA and recFSH, with vital pregnancy rate defined as the percentage of subjects with at least one foetus with heart activity assessed 5 to 6 weeks after embryo transfer.

The pregnancy results from the fresh cycles of ENGAGE and PURSUE are summarized in Table 2 below.

Table 2: Pregnancy Results from the Fresh Cycles of ENGAGE and PURSUE Intent-to-Treat Population (ITT)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Fresh Cycles of ENGAGE† (18-36 years of age) (body weight greater than 60 kg and less than or equal to 90 kg)</th>
<th>Fresh Cycles of PURSUE† (35-42 years of age) (body weight greater than or equal to 50 kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ELONVA 150 µg recFSH 200 IU</td>
<td>Difference [95% CI]</td>
</tr>
<tr>
<td>N=756</td>
<td>N=750</td>
<td></td>
</tr>
<tr>
<td>Vital pregnancy rate</td>
<td>39.9%</td>
<td>39.1%</td>
</tr>
<tr>
<td>Ongoing pregnancy rate</td>
<td>39.0%</td>
<td>38.1%</td>
</tr>
<tr>
<td>Parameter</td>
<td>Fresh Cycles of ENGAGE†</td>
<td>Fresh Cycles of PURSUE‡</td>
</tr>
<tr>
<td>-----------</td>
<td>------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td></td>
<td>(18-36 years of age)</td>
<td>(35-42 years of age)</td>
</tr>
<tr>
<td></td>
<td>(body weight greater than 60 kg and less than or equal to 90 kg)</td>
<td>(body weight greater than or equal to 50 kg)</td>
</tr>
<tr>
<td>ELONVA 150 µg</td>
<td>recFSH 200 IU</td>
<td>Difference [95% CI]</td>
</tr>
<tr>
<td>N=756</td>
<td>N=750</td>
<td>35.6% 34.4% 1.3 [-3.5, 6.1]</td>
</tr>
<tr>
<td>Live birth rate*</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FTET Cycles of ENGAGE (18-36 years of age)</th>
<th>FTET Cycles of PURSUE (35-42 years of age)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(body weight greater than 60 kg and less than or equal to 90 kg)</td>
<td>(body weight greater than or equal to 50 kg)</td>
</tr>
<tr>
<td>ELONVA 150 µg</td>
<td>recFSH 200 IU</td>
</tr>
<tr>
<td>n N %</td>
<td>n N %</td>
</tr>
</tbody>
</table>

†The primary efficacy endpoint in the ENGAGE study was ongoing pregnancy (assessed at least 10 weeks after embryo transfer).
‡The primary efficacy endpoint in the PURSUE study was vital pregnancy rate defined as the percentage of subjects with at least one foetus with heart activity assessed 5 to 6 weeks after embryo transfer.
*Live birth rate was a secondary efficacy endpoint in ENGAGE and PURSUE.

In these comparative clinical trials, the safety profile of a single injection of ELONVA was comparable to daily injections with recFSH.

Pregnancy from the Frozen-Thawed Embryo Transfer (FTET) cycles of ENGAGE and PURSUE
The follow-up FTET trial for ENGAGE included women who had at least one embryo thawed for use up to at least one year after cryopreservation. The mean number of embryos transferred in the FTET cycles of ENGAGE was 1.7 in both treatment groups.

The follow-up FTET trial for PURSUE included women who had at least one embryo thawed for use within two years of the date of the last cryopreservation for this trial. The mean number of embryos transferred in the FTET cycles of PURSUE was 2.4 in both treatment groups. This trial also provided safety data on the infants born from cryopreserved embryos.

The pregnancy results from the FTET cycles of ENGAGE and PURSUE are summarised in Table 3 below.

Table 3: Pregnancy Results from the FTET cycles of ENGAGE and PURSUE
Intent-to-Treat Population (ITT)
Pregnancy from the addition of FTET cycles to the fresh cycles of ENGAGE and PURSUE (Cumulative Vital Pregnancy Rates)

The cumulative vital pregnancy rate (per subject and per cycle) was calculated based on the results of the fresh and subsequent FTET cycles of a single cohort of women who received ELONVA or recFSH in ENGAGE or PURSUE.

The cumulative vital pregnancy rate from ENGAGE in subjects treated with a single injection of 150 μg ELONVA was similar to that in subjects treated with daily 200 IU recFSH.

The cumulative vital pregnancy rate from PURSUE in subjects treated with a single injection of 150 μg ELONVA was similar to that in subjects treated with daily 300 IU recFSH.

The pregnancy results are summarised in Table 4 below.

<table>
<thead>
<tr>
<th>Ongoing pregnancy</th>
<th>FTET Cycle 4&lt;sup&gt;a&lt;/sup&gt;</th>
<th>FTET Cycle 5&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 9 11.1 0 4 0.0 2 5 40.0 1 4 25.0</td>
<td>0 3 0.0 0 1 0.0 0 1 0.0 2 2 100.0</td>
</tr>
<tr>
<td>Live birth</td>
<td>- - - - - - 2 5 40.0 1 4 25.0</td>
<td>- - - - - - 0 1 0.0 2 2 100.0</td>
</tr>
</tbody>
</table>

n = number of subjects with the event; N = total number of subjects
<sup>a</sup>Per embryo transfer.

Table 4: Pregnancy Results from fresh ART cycles combined with FTET cycles of ENGAGE and PURSUE Intent-to-Treat Population (ITT)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>ENGAGE (18-36 years of age)</th>
<th>PURSUE (35-42 years of age)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(body weight greater than 60 kg and less than or equal to 90 kg)</td>
<td>(body weight greater than or equal to 50 kg)</td>
</tr>
<tr>
<td>ELONVA 150 μg</td>
<td>recFSH 200 IU</td>
<td>ELONVA 150 μg</td>
</tr>
<tr>
<td>Cumulative vital pregnancy rate per subject&lt;sup&gt;†&lt;/sup&gt;</td>
<td>N=756</td>
<td>N=750</td>
</tr>
<tr>
<td>48.1%</td>
<td>46.0%</td>
<td>31.1%</td>
</tr>
<tr>
<td>Cumulative vital pregnancy rate per cycle&lt;sup&gt;‡&lt;/sup&gt;</td>
<td>Nc=980</td>
<td>Nc=974</td>
</tr>
<tr>
<td>37.7%</td>
<td>35.8%</td>
<td>25.6%</td>
</tr>
</tbody>
</table>

N=Number of subjects
Nc=Number of cycles
<sup>†</sup>The cumulative vital pregnancy rate was calculated per subject and is based on fresh and frozen-thawed embryo transfer (FTET) cycles from ENGAGE and PURSUE.
<sup>‡</sup>The cumulative vital pregnancy rate was calculated per cycle and is based on fresh and frozen-thawed embryo transfer (FTET) cycles from ENGAGE and PURSUE.
Congenital malformations reported in infants born after a frozen-thawed embryo transfer (FTET) cycle
Following use of ELONVA, 61 infants were born after an FTET cycle in the PURSUE study follow-up, and 607 infants were born after fresh ART cycles in the ENSURE, ENGAGE and PURSUE studies combined. The rates for congenital malformations (major and minor combined) reported for infants born after an FTET cycle in the PURSUE study follow-up (16.4%) were similar to those reported for infants born after fresh ART cycles in the ENSURE, ENGAGE and PURSUE studies combined (16.8%).

Immunogenicity
Of the 2,511 women treated with ELONVA who were evaluated for the formation of post-treatment antibodies, four (0.16%) had evidence of antibody formation, including three who had been exposed once to ELONVA and one who had been exposed twice to ELONVA. In each case, these antibodies were non-neutralising and did not interfere with the response to stimulation or the normal physiologic responses of the Hypothalamic-Pituitary-Ovarian (HPO) axis. Two of these four women became pregnant during the same treatment cycle in which antibodies were detected, suggesting that the presence of non-neutralising antibodies after stimulation with ELONVA is not clinically relevant.

Cardiac Electrophysiology
In a randomized, double-blind, placebo- and active-controlled, 4-period crossover study, 70 healthy postmenopausal women received a single therapeutic dose of 150 mcg of corifollitropin alfa subcutaneously, a single supratherapeutic dose of 240 mcg of corifollitropin alfa subcutaneously, 400 mg moxifloxacin orally, and placebo. Both doses of corifollitropin alfa did not appear to prolong the QTc interval for up to 216 hours postdose. After baseline and placebo adjustment, the maximum mean QTc interval change after administration of a therapeutic dose of 150 mcg of corifollitropin alfa was 1.4 msec (1-sided 95% upper CI: 3.4 msec). After administration of the supratherapeutic dose of 240 mcg of corifollitropin alfa, the maximum mean QTc interval change was 1.2 msec (1-sided 95% upper CI: 3.6 msec).

5.2 Pharmacokinetic properties
Pharmacokinetic parameters of corifollitropin alfa were evaluated after subcutaneous administration in women undergoing a COS treatment cycle.

Due to the long elimination half-life, after administration of the recommended dose, serum concentrations of corifollitropin alfa are sufficient to sustain multiple follicular growth for an entire week. Therefore, with a single subcutaneous injection of ELONVA may be used as an alternative to the first seven days of daily rec(FSH) in COS for the development of multiple follicles and pregnancy in women undergoing in vitro fertilisation techniques (see section 4.2).

Body weight is a determinant of exposure to corifollitropin alfa. The mean corifollitropin alfa exposure (AUC) after a single subcutaneous injection is 665 hours*ng/mL (426-1,037 hours*ng/mL) and is similar after administration of 100 micrograms corifollitropin alfa to women with a body weight less than or equal to 60 kilograms and of 150 micrograms corifollitropin alfa to women with a body weight greater than 60 kilograms. [ Predicted range for 90% of subjects].

Absorption
After a single subcutaneous injection of ELONVA, the mean maximum serum concentration (Cmax) of corifollitropin alfa is 4.24 ng/mL (2.49-7.21 ng/mL) and is reached at the mean Tmax of 44 hours (35-57 hours) postdose. The absolute bioavailability is 58% (48-70%). [ Predicted range for 90% of subjects].

Distribution
Distribution, metabolism and elimination of corifollitropin alfa are very similar to other gonadotrophins, such as FSH, hCG and LH. After absorption into the blood, corifollitropin alfa is distributed mainly to the ovaries and the kidneys. Elimination of corifollitropin alfa predominantly occurs via the kidneys. The steady state volume of distribution is 9.2 L (6.5-13.1 L). Exposure to corifollitropin alfa increases proportionally with dose within the range of 60 micrograms to 240 micrograms. [ Predicted range for 90% of subjects].
Elimination
Corifollitropin alfa has a mean elimination half-life ($t_{1/2}$) of 70 hours (59-82 hours$^1$) and a clearance of 0.13 L/h (0.10-0.18 L/h$^1$). Elimination of corifollitropin alfa predominantly occurs via the kidneys, and the rate of elimination may be reduced in patients with renal insufficiency (see sections 4.4 and 4.2). [1 Predicted range for 90% of subjects]. Hepatic metabolism contributes to a minor extent to the elimination of corifollitropin alfa.

Other special populations
Hepatic impairment
Although data in hepatically impaired patients are not available, hepatic impairment is unlikely to affect the pharmacokinetic profile of corifollitropin alfa.

5.3 Preclinical safety data
Administration of corifollitropin alfa to rats and rabbits, prior to and directly after mating, and during early pregnancy, resulted in embryotoxicity. In rabbits, when administered prior to mating, teratogenicity has been observed. Both embryotoxicity and teratogenicity are considered a consequence of the superovulatory state of the animal not able to support a number of embryos above a physiological ceiling. The relevance of these findings for the clinical use of ELONVA is limited.

Carcinogenicity
Long-term carcinogenicity studies in animals have not been performed to evaluate the carcinogenic potential of corifollitropin alfa.

Genotoxicity
Corifollitropin alfa was not mutagenic or clastogenic in the standard battery of tests.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients
ELONVA also contains the excipients sodium citrate, sucrose, polysorbate 20, methionine, sodium hydroxide and/or hydrochloric acid (for pH adjustment), and Water for Injections.

6.2 Incompatibilities
In the absence of compatibility studies, the solution for injection must not be mixed with other medicinal products.

6.3 Shelf life
3 years

6.4 Special precautions for storage
Store at 2°C to 8°C (Refrigerate. Do not freeze). Keep the syringe in the outer carton. Product is for single use in one patient only. Contains no antimicrobial preservative. Discard any residue. Do not use after the expiry date on the carton.

ELONVA can also be stored below 25°C for up to 1 month. Do not use after this period.

6.5 Nature and contents of container
ELONVA is supplied in disposable 1-mL luerlock syringes of hydrolytic glass (type I), closed with a rubber plunger and a tip cap. The syringes are packed together with a sterile injection needle.

Pack size: 1 pre-filled syringe equipped with an automatic safety system to prevent needle stick injuries after use.

6.6 Special precautions for disposal
No information
7. MEDICINE SCHEDULE
Prescription Only Medicine

8. SPONSOR
Merck Sharp & Dohme (NZ) Ltd
PO Box 99 851
Newmarket
Auckland 1149
Tel: 0800 500 673

9. DATE OF FIRST APPROVAL
8 March 2012

10. DATE OF REVISION OF THE TEXT
25 June 2018

SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Version #</th>
<th>CCDS document code</th>
<th>Release Date</th>
<th>Sections revised</th>
<th>Brief Description of Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>CCDS-MK8962-SOi-062017</td>
<td>June 2017</td>
<td>4.8 Undesirable effects</td>
<td>Addition of uncommon undesirable effect “Mood swings”</td>
</tr>
</tbody>
</table>